-transparent.png){kind=logo}
Previous studies indicate that decreased serum viral infectivity and viral antigen levels follow oral administration of diethylcarbamazine (DEC) in feline leukemia virus infected cats, even though DEC has not been shown to exhibit in vitro antiviral activity. In this investigation, DEC was given by oral administration or (single dose) IP injection to murine leukemia virus (Cas-Br-M) inoculated mice to permit evaluation of its effect on viral-induced central nervous system disease. The survival of Cas-Br-M inoculated mice receiving DEC in water was significantly prolonged relative to similarly inoculated mice receiving distilled water. Among the Cas-Br-M inoculated mice euthanatized after the study, higher body weights and trend toward less severe brain and splenic lesions were noted in those receiving DEC in drinking water. Given these results, the possible utility of DEC in treatment of retroviral and other infections warrants further study.
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
January 1985,
Journal of virology,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
March 2000,
Virology,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
January 1993,
Viral immunology,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
December 1994,
AIDS research and human retroviruses,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
February 1984,
Journal of the National Cancer Institute,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
November 1993,
Journal of virology,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
September 1996,
Veterinary immunology and immunopathology,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
November 1985,
Journal of virology,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
October 1980,
Biochemical genetics,
L W Kitchen, and
F J Mather, and
F E Chapple, and
J A Bilello
January 1978,
Journal of surgical oncology,
